Processing...
Clinical Trials for Prostate Cancer
Search
Search
There are 228 active trials for advanced/metastatic prostate cancer.
Click on a trial to see more information.
228 trials meet filter criteria.
Sort by:
TrialFetch AI summary: Enrolls adults with advanced malignancies, primarily HR+/HER2− advanced breast cancer that has progressed after endocrine therapy plus a CDK4/6 inhibitor (phase II limited to ≤2 prior endocrine lines for advanced disease and no prior chemotherapy/ADC in the advanced setting), with additional phase I cohorts for CCNE1-amplified solid tumors and metastatic castration-resistant prostate cancer. Patients receive the first-in-human investigational agent GVV858 (target/mechanism not publicly specified) as monotherapy or combined with endocrine therapy—fulvestrant (and letrozole in phase I), with phase II evaluating two GVV858 dose regimens plus fulvestrant.
ClinicalTrials.gov ID: NCT07288359
TrialFetch AI summary: Enrolls adults with progressive metastatic castration-resistant prostate adenocarcinoma after at least one prior novel androgen receptor pathway inhibitor, requiring PSMA-positive disease on PSMA PET (with RECIST-measurable disease or evaluable disease with PSA ≥1 ng/mL) and no CNS metastases. Patients undergo leukapheresis and receive a single IV infusion of AB-3028, an autologous logic-gated engineered T-cell therapy designed to activate only with PSMA plus a second priming antigen to improve tumor selectivity and limit on-target/off-tumor toxicity.
ClinicalTrials.gov ID: NCT07285694
TrialFetch AI summary: Adults with advanced/metastatic adrenocortical carcinoma or metastatic castration-resistant prostate cancer (ECOG 0–1; ECOG 2 allowed if due to cancer pain), with the mCRPC cohort requiring prior androgen receptor pathway inhibitor exposure and at least one prior chemotherapy line or ineligibility/refusal, receive oral DS9051b tablet monotherapy. This dose-escalation study is primarily assessing safety/DLTs and establishing the recommended expansion dose while looking for preliminary antitumor activity; DS9051b’s target/mechanism has not been publicly specified.
ClinicalTrials.gov ID: NCT07189403
TrialFetch AI summary: Eligible patients are men with metastatic castration-resistant prostate adenocarcinoma (ECOG 0–1, PSA ≥2 ng/mL) with progression on androgen-deprivation therapy and at least one prior approved secondary hormonal therapy for CRPC, without prior/active brain metastases or significant cardiac disease. Participants receive BMS-986460 monotherapy, an investigational ligand-directed degrader that binds a prostate tumor-associated antigen and recruits an E3 ubiquitin ligase to promote ubiquitination and proteasome-mediated degradation of a target protein in tumor cells.
ClinicalTrials.gov ID: NCT06067841
TrialFetch AI summary: Enrolls adults with metastatic castration-resistant prostate adenocarcinoma (ECOG 0–1) progressing on androgen deprivation therapy after at least one prior androgen receptor pathway inhibitor and 1–2 prior taxane chemotherapy regimens, excluding small cell/neuroendocrine histology and prior AR degrader therapy. Single-arm dose-escalation/optimization study of GSK5471713 monotherapy (reported as an investigational androgen receptor degrader) to define safety/PK and look for early PSA and radiographic responses.
ClinicalTrials.gov ID: NCT07332455
TrialFetch AI summary: Adults with ECOG 0–1 and locally advanced/metastatic solid tumors, including ER+/HER2− breast cancer, NSCLC, CRPC, and MSS colorectal cancer after prior standard therapy, receive oral IDE574 monotherapy; breast cancer cohorts require prior endocrine therapy and CDK4/6 inhibitor. ER+/HER2− breast cancer patients may receive IDE574, an investigational dual KAT6/KAT7 epigenetic inhibitor, in combination with fulvestrant.
ClinicalTrials.gov ID: NCT07540572
TrialFetch AI summary: Adults with ECOG 0–1 and measurable locally advanced/metastatic solid tumors co-expressing B7-H3 and PTK7, after progression/intolerance to prior therapy or lacking standard options, including NSCLC, ESCC, endometrial, ovarian, HNSCC, TNBC, colorectal, and CRPC. All participants receive IDE034, an investigational bispecific B7-H3/PTK7 antibody–drug conjugate with a topoisomerase I inhibitor payload, in dose-escalation and expansion cohorts.
ClinicalTrials.gov ID: NCT07503808
TrialFetch AI summary: Adults with ECOG 0–1 and measurable advanced selected solid tumors, including SCLC, extrapulmonary high-grade neuroendocrine/small-cell carcinomas, NSCLC, prostate, ovarian, renal, HNSCC, hepatic, gastric, and triple-negative breast cancers, after progression/relapse/intolerance to at least one standard systemic therapy. All patients receive dose-escalated oral EXS74539/REC-4539 monotherapy, a selective reversible LSD1/KDM1A epigenetic inhibitor, to define safety and MTD with preliminary efficacy assessment.
ClinicalTrials.gov ID: NCT07517198
TrialFetch AI summary: Adults with unresectable or metastatic advanced solid tumors, particularly MSI-H/dMMR tumors, receive oral EIK1005, a Werner syndrome helicase inhibitor intended to exploit synthetic lethality in MSI-H cancers, after progression/intolerance of standard therapy or in dose-optimization cohorts. The study tests EIK1005 monotherapy and dose escalation of EIK1005 plus pembrolizumab in MSI-H/dMMR advanced solid tumors.
ClinicalTrials.gov ID: NCT07262619
TrialFetch AI summary: Enrolls men with metastatic castration-resistant prostate adenocarcinoma, generally after prior androgen receptor pathway inhibitor therapy and limited/required prior taxane exposure depending on cohort, with key exclusions including prior T-cell engager/CAR-T or radioligand therapy. All participants receive single-agent JANX014, an investigational tumor-activated PSMA × CD3 T-cell engager designed to redirect T cells against PSMA-expressing prostate cancer cells while limiting systemic T-cell activation.
ClinicalTrials.gov ID: NCT07545811